Intended for US Audience Only

ONCASPAR (pegaspargase)

Welcome!

ONCASPAR (pegaspargase) is given to patients with acute lymphoblastic leukemia (ALL) as part of a group of chemotherapy medications. ONCASPAR is administered IM/IV* and should not be given more frequently than every 14 days.

For more information, see the Indication and Important Safety Information below, and download the Full Prescribing Information here.

Baxalta's Resource Helpline

Questions about patient assistance programs, co-pay assistance, and connections to reimbursement specialists should be directed to Baxalta's Resource Helpline.

US toll-free number: Call 1-888-BAX-8379
Puerto Rico toll-free number: Call 1-844-229-7575

*IM=Intramuscular; IV=Intravenous.

Indication

ONCASPAR (pegaspargase) is indicated as a component of a multiagent chemotherapeutic regimen for the first-line treatment of patients with acute lymphoblastic leukemia (ALL) and for the treatment of patients with ALL and hypersensitivity to native forms of L-asparaginase.

Important Safety Information

ONCASPAR is contraindicated in patients with a history of serious allergic reactions to ONCASPAR, and in patients with a history of serious thrombosis, pancreatitis, or serious hemorrhagic events with prior L-asparaginase therapy.

Anaphylaxis or serious allergic reactions can occur; therefore, patients should be observed for one hour after administration. Discontinue ONCASPAR in patients with serious allergic reactions.

Patients with abdominal pain should be evaluated for evidence of pancreatitis. Discontinue ONCASPAR in patients with pancreatitis. ONCASPAR should also be discontinued in patients with serious thrombotic events.

Glucose intolerance, in some cases irreversible, can occur; serum glucose should be monitored. Coagulopathy and hepatotoxicity can occur; appropriate monitoring should be performed.

The most common adverse reactions with ONCASPAR (≥2%) are allergic reactions (including anaphylaxis), hyperglycemia, pancreatitis, central nervous system (CNS) thrombosis, coagulopathy, hyperbilirubinemia, and elevated transaminases.

Hyperlipidemia (hypercholesterolemia and hypertriglyceridemia) has been reported in patients exposed to ONCASPAR.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Baxalta and Oncaspar are trademarks of Baxalta Incorporated, its subsidiaries or affiliates.

All other product brands or trademarks appearing herein are the property of their respective owners.

Legal Disclaimer Privacy